PetVivo Reports Financial and Operational Results for Fiscal 2026
PetVivo reported fiscal 2026 revenue of $1.14 million, essentially flat year-over-year, while net loss widened to $10.9 million. The company’s cash balance dropped to approximately $200,000, which appears insufficient to cover its roughly $9.8 million in annual operating expenses without immediate financing. Operationally, the company secured Health Canada authorization for its Spryng device and launched beta versions of its AI veterinary platforms, AgenticPet and PetVivo.ai. The company also announced the subsequent acquisition of R&D partner PiezoBioMembrane.
Key figures
- Revenue
- 1141607
- Revenue Yoy
- 0.8%
- Cash
- 200782
- Net loss
- 10473672
- Operating loss
- 9062962
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.